胆道がん市場- 世界の産業規模、シェア、動向、機会、予測、がんタイプ別、エンドユーザー別、地域別、競争別、2020～2030年

胆道がんの世界市場規模は2024年に6億4,505万米ドルとなり、2030年のCAGRは4.75%で、予測期間中に着実な成長が予測されています。

世界の胆道がん市場は、より広範な腫瘍学セグメントの中でダイナミックに進化しているセグメントです。胆管と胆嚢のがんを含む胆道がんは、医療産業にユニークな課題と機会をもたらします。本市場概要では、世界の胆道がん市場の現状を明らかにすることを目的とします。

胆道がんは、他のがんに比べて比較的まれではあるが、近年増加傾向にあります。ライフスタイルの変化、肥満率の増加、環境毒素への曝露、肝インフルエンザ感染のような特定の危険因子などの要因が、この疾患の罹患率上昇に寄与しています。胆道がんの有病率を理解することは、市場利害関係者が潜在的な患者集団を評価する上で極めて重要です。

主要市場促進要因

胆道がん（BTC）の発生率と有病率の増加

主要市場課題

認知度の低下と診断の遅れ

主要市場動向

治療アプローチに革命をもたらす免疫療法

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 胆道がん市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • がんタイプ別（肝内胆管がん（ICC）、肝外胆管がん、胆嚢がん）
  • エンドユーザー別（病院、専門がんセンター、外来手術センター、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の胆道がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の胆道がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の胆道がん市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の胆道がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの胆道がん市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 製品上市
• 合併と買収

第13章 世界の胆道がん市場：SWOT分析

第14章 競合情勢

• Bristol-Myers Squibb
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Bayer AG
• AstraZeneca plc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Biliary Tract Cancers Market was valued at USD 645.05 Million in 2024 and is anticipated to project Steady growth in the forecast period with a CAGR of 4.75% through 2030. The Global Biliary Tract Cancer Market is a dynamic and evolving sector within the broader field of oncology. Biliary tract cancer, which includes cancers of the bile ducts and gallbladder, poses unique challenges and opportunities for the healthcare industry. This market overview aims to shed light on the current state of the Global Biliary Tract Cancer Market.

Biliary tract cancer, while relatively rare compared to some other cancers, has been on the rise in recent years. Factors such as changing lifestyles, increased obesity rates, exposure to environmental toxins, and specific risk factors like liver fluke infections have contributed to the increasing incidence of this disease. Understanding the prevalence of biliary tract cancer is crucial for market stakeholders to assess the potential patient population.

Key Market Drivers

Increasing Incidence and Prevalence of Biliary Tract Cancers (BTCs)

The increasing incidence and prevalence of biliary tract cancers (BTCs) are key market drivers that significantly impact the Global Biliary Tract Cancers Market. According to the Global Burden of Disease Study, the global age-standardized incidence rate (ASR) for biliary tract cancers (BTCs) is 2.5 cases per 100,000 individuals. However, incidence rates vary significantly based on tumor location (intrahepatic vs. extrahepatic cholangiocarcinoma, gallbladder cancer), geographic region, and gender, reflecting differences in genetic predisposition, environmental risk factors, and healthcare accessibility across populations. This rising trend is fueling demand for diagnostics, therapeutics, and supportive care solutions, creating lucrative opportunities for pharmaceutical companies, biotech firms, and healthcare providers. The growing number of diagnosed BTC cases worldwide is directly increasing the demand for treatment options. The Global Burden of Disease Study reported 139,500 deaths from biliary tract cancers (BTCs) in 2013, marking a 22% increase from the 115,400 deaths recorded in 1990. This rise corresponds to an increase in the age-standardized mortality rate, from 2.3 deaths per 100,000 individuals per year in 1990 to 3.4 per 100,000 per year in 2013, highlighting a growing disease burden and the need for enhanced diagnostic and treatment strategies. With biliary tract cancers being aggressive and often diagnosed at advanced stages, the need for effective chemotherapy, targeted therapies, and immunotherapies is rising. Increased drug sales for existing therapies. Greater investment in clinical research and drug development. Expansion of treatment facilities and specialized cancer centers.

Key Market Challenges

Limited Awareness and Late-Stage Diagnoses

One of the foremost challenges facing the Global Biliary Tract Cancer Market is the limited awareness among the general population and healthcare providers regarding this particular cancer type. Biliary tract cancer often presents with non-specific symptoms, leading to delayed diagnoses. Many individuals and even some healthcare professionals may not be adequately familiar with these symptoms, which can include jaundice, abdominal pain, and unexplained weight loss.

The lack of early detection can result in patients being diagnosed at advanced stages of the disease, when treatment options are more limited and prognosis is less favorable. This not only hampers patient outcomes but also reduces the potential market size for early-stage therapies and interventions.

Key Market Trends

Immunotherapy Revolutionizing Treatment Approaches

One of the most significant trends shaping the Global Biliary Tract Cancer Market is the emergence of immunotherapy as a promising treatment option. Immunotherapeutic agents, such as immune checkpoint inhibitors, have shown remarkable efficacy in various cancer types, including biliary tract cancer. These agents work by stimulating the body's immune system to recognize and target cancer cells, offering new hope for patients.

The trend towards immunotherapy is driven by a growing body of clinical evidence supporting its effectiveness. Clinical trials have demonstrated prolonged survival rates and improved outcomes for patients with advanced biliary tract cancer. This has led to increased research and investment in immunotherapeutic approaches, with pharmaceutical companies developing novel drugs and therapies targeting this specific cancer type.

Key Market Players

• Bristol-Myers Squibb
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Bayer AG
• AstraZeneca plc

Report Scope:

In this report, the Global Biliary Tract Cancers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biliary Tract Cancers Market, By Cancer Type:

• Intrahepatic Cholangiocarcinoma (ICC)
• Extrahepatic Cholangiocarcinoma
• Gallbladder Cancer

Biliary Tract Cancers Market, By End-User:

• Hospitals
• Specialty Cancer Centres
• Ambulatory Surgical Centres
• Others

Biliary Tract Cancers Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biliary Tract Cancers Market.

Available Customizations:

Global Biliary Tract Cancers market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Biliary Tract Cancers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Intrahepatic Cholangiocarcinoma (ICC), Extrahepatic Cholangiocarcinoma, Gallbladder Cancer)
  • 5.2.2. By End-User (Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Biliary Tract Cancers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biliary Tract Cancers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Biliary Tract Cancers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Biliary Tract Cancers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By End User

7. Europe Biliary Tract Cancers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Biliary Tract Cancers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By End User
  • 7.3.2. United Kingdom Biliary Tract Cancers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Italy Biliary Tract Cancers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By End User
  • 7.3.4. France Biliary Tract Cancers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Biliary Tract Cancers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By End User

8. Asia-Pacific Biliary Tract Cancers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Biliary Tract Cancers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Biliary Tract Cancers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Biliary Tract Cancers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Biliary Tract Cancers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Biliary Tract Cancers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By End User

9. South America Biliary Tract Cancers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Biliary Tract Cancers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Biliary Tract Cancers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Biliary Tract Cancers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By End User

10. Middle East and Africa Biliary Tract Cancers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Biliary Tract Cancers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Biliary Tract Cancers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Biliary Tract Cancers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Biliary Tract Cancers Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Bristol-Myers Squibb
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Eli Lilly and Company
• 14.3. F. Hoffmann-La Roche Ltd.
• 14.4. Johnson & Johnson Services, Inc
• 14.5. Merck & Co., Inc.
• 14.6. Novartis AG
• 14.7. Pfizer Inc.
• 14.8. Sanofi SA
• 14.9. Bayer AG
• 14.10.AstraZeneca plc

15. Strategic Recommendations

16. About Us & Disclaimer